Comparison of Pregabalin and Ketotifen in treatment of uremic pruritus in hemodialysis patients.
Ketotifen
Pregabalin
uremic pruritus
Journal
Dermatologic therapy
ISSN: 1529-8019
Titre abrégé: Dermatol Ther
Pays: United States
ID NLM: 9700070
Informations de publication
Date de publication:
07 2022
07 2022
Historique:
revised:
03
05
2022
received:
26
01
2022
accepted:
08
05
2022
pubmed:
14
5
2022
medline:
15
7
2022
entrez:
13
5
2022
Statut:
ppublish
Résumé
This study aims to compare the efficiency of Pregabalin and Ketotifen in treatment of uremic pruritus in hemodialysis (HD) patients. Thirty HD patients were randomly divided into two groups: A (Pregabalin 50 mg three times a day) and B (Ketotifen 1 mg twice a day). Efficacy of treatment and quality of life were weekly evaluated by visual analogue scale (VAS) and Itchy Quality of life, respectively. There was no significant difference between the two groups regarding demographic features, laboratory data, quality of life, and VAS before treatment. In the second week of treatment, the pruritus intensity was significantly lower in the Pregabalin group than the Ketotifen group (p = 0.026). The mean of life quality was significantly lower in Ketotifen than Pregabalin group in weeks 1, 2, and 4 (p = 0.001, p = 0.001, and p = 0.036, respectively). There was no significant difference between the two groups regarding the side effects of drugs. This study showed that a higher dose of Pregabalin could be a more effective treatment than Ketotifen without additive side effects in improving the quality of life in dialysis patients.
Substances chimiques
Pregabalin
55JG375S6M
Ketotifen
X49220T18G
Types de publication
Journal Article
Randomized Controlled Trial
Langues
eng
Sous-ensembles de citation
IM
Pagination
e15579Informations de copyright
© 2022 Wiley Periodicals LLC.
Références
Shirazian S, Aina O, Park Y, et al. Chronic kidney disease-associated pruritus: impact on quality of life and current management challenges. Int J Nephrol Renovasc Dis. 2017;23(10):11-26.
Westby E, Purdy K, Tennankore K. A review of the management of uremic pruritus: current perspectives and future directions, Itch; 2020:e38
Foroutan N, Nikvarz N. Role of Pregabalin in Management of Pruritus: a literature review. J Pharm Pharm Sci. 2016;19(4):465-474.
Rayner HC, Larkina M, Wang M, et al. International comparisons of prevalence, awareness, and treatment of pruritus in people on hemodialysis. Clin J Am Soc Nephrol. 2017;12:2000-2007. doi:10.2215/CJN.03280317
Lee J, Jang D, Bae J, Jung H, Park M. Efficacy of Pregabalin for the treatment of chronic pruritus of unknown origin, assessed based on electric current perception threshold. Scientific Rep Nat. 2020;10:22.
Foroutan N, Etminan A, Nikvarz N, Shojai Shahrokh Abadi M. Comparison of Pregabalin with doxepin in the management of uremic pruritus: a randomized single blind clinical trial. Hemodial Int. 2017;21(1):63-71.
Yue J, Jiao S, Xiao Y, Ren W, Zhao T, Meng J. Comparison of Pregabalin with ondansetron in treatment of uremic pruritus in dialysis patients: a prospective, randomized, double-blind study. Int Urol Nephrol. 2015;47(1):161-167.
Ravindran A, Peringanazhi Kunnath R, Sunny A, Vimal B. Comparison of safety and efficacy of Pregabalin versus gabapentin for the treatment of uremic pruritus in patients with chronic kidney disease on maintenance hemodialysis. Indian Journal of Palliative Care. 2020;26(3):281-286.
Otsuki T, Higuchi T, Yamazaki T, Okawa E, Okada K, Abe M. Efficacy and safety of Pregabalin for the treatment of neuropathic pain in patients undergoing hemodialysis. Clin Drug Investig. 2017;37:95-102.
Sreekantaswamy S, Mollanazar N, Butler D. Gabapentinoids for pruritus in older adults. A narrative review. Dermatol Ther (Heidelb). 2021;11:669-679.
Ohishi A, Chisaki Y, Hira D, Nagasawa K, Terada T. Opioid analgesics increase incidence of somnolence and dizziness as adverse effects of Pregabalin: a retrospective study. J Pharm Health Care Sci. 2015;1:30.